A Study Assessing Short-Course Radiation Therapy Plus Chemotherapy for Endometrial Cancer


Full Title

A Feasibility Study of Integrated Delivery of Hypofractionated Pelvic IMRT with Carboplatin and Paclitaxel in Stage III Copy-Number Low and Copy-Number High Subtypes of Endometrial Cancer


After endometrial cancer surgery, there is a risk that the cancer will come back. Combining a shorter course of radiation treatment with chemotherapy may decrease the chance of endometrial cancer recurring.

In this study, participants will receive one week of radiation therapy (instead of the usual five weeks) plus chemotherapy with carboplatin and paclitaxel, which are given intravenously (by vein). Researchers are doing this study to determine if this combination of therapies is practical, meaning that most participants can complete the treatment schedule.

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have stage IIIA or IIIC1 endometrial cancer that was surgically removed.
  • Patients’ tumors must be molecular subtypes “copy-number low” or “copy-number high,” which will be determined through molecular testing at Memorial Sloan Kettering.
  • Prior chemotherapy, radiation therapy, or hormonal therapy for endometrial cancer is not permitted.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Kaled Alektiar at 212-639-7981.




Pilot (small research study)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID